Burning Rock Biotech has partnered with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) to enable treatment choices for cancer patients in China.
The partnership aims to advance CDx products in China, targeting Bayer's expanding range of precision cancer treatments. Burning Rock states that by combining resources and expertise in cancer diagnosis and treatment, the collaboration is aimed to set a benchmark standard for precision oncology in China.
Burning Rock is a biotechnology company specializing in applying NGS technology in precision oncology. Its services encompass NGS-based therapy selection testing for late-stage cancer patients, global pharmaceutical services for biomarker detection and CDx solutions development, and early cancer detection.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.